摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methoxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridine | 1056549-88-2

中文名称
——
中文别名
——
英文名称
2-methoxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
英文别名
——
2-methoxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridine化学式
CAS
1056549-88-2
化学式
C8H11NOS
mdl
——
分子量
169.247
InChiKey
DSDPPPHRTAPVEV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    304.5±42.0 °C(Predicted)
  • 密度:
    1.160±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    49.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-methoxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridine盐酸 、 sodium hydride 、 potassium carbonate 作用下, 以 四氢呋喃乙醇N,N-二甲基甲酰胺 为溶剂, 反应 12.0h, 生成 普拉格雷
    参考文献:
    名称:
    Efficient synthesis of prasugrel, a novel P2Y12 receptor inhibitor
    摘要:
    An efficient synthesis of prasugrel, a novel P2Y(12) receptor inhibitor, is described. The cyclopropyl-phenyl-ethanone intermediate was prepared by cyanide substitution, bromination, N-substitution, and the Grignard reaction. After acid hydrolyzation of the methyl ether and subsequent acetylation, the title product was obtained with a total yield of 21% after 10 linear steps from simple and commercially available raw materials. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2012.07.071
  • 作为产物:
    参考文献:
    名称:
    Efficient synthesis of prasugrel, a novel P2Y12 receptor inhibitor
    摘要:
    An efficient synthesis of prasugrel, a novel P2Y(12) receptor inhibitor, is described. The cyclopropyl-phenyl-ethanone intermediate was prepared by cyanide substitution, bromination, N-substitution, and the Grignard reaction. After acid hydrolyzation of the methyl ether and subsequent acetylation, the title product was obtained with a total yield of 21% after 10 linear steps from simple and commercially available raw materials. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2012.07.071
点击查看最新优质反应信息

文献信息

  • [EN] A PROCESS FOR MAKING PRASUGREL<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PRASUGREL
    申请人:SYNTHON BV
    公开号:WO2011110219A1
    公开(公告)日:2011-09-15
    The present invention relates to A compound of general Formula (A), and/or acid addition salts thereof, wherein R is a hydrogen atom or a nitrogen-protecting group or an alpha- cyclopropylcarbonyl-2-fluorobenzyl group and R1,R2 is independently a C1-C10 alkyl group, optionally having one or more carbons substituted by a hydroxy group, or R1,R2 together with the bridging nitrogen may form a ring comprising from 3 to 10 carbon atoms, optionally also comprising another nitrogen, oxygen or sulfur atom in the ring and/or a nitrogen-, oxygen-, or sulfur-comprising substituent on the ring, to a process of making and use in making prasugrel.
    本发明涉及一般式(A)的化合物,及/或其酸盐,其中R是氢原子或氮保护基或α-环丙基羰基-2-氟苄基基团,而R1、R2独立地是C1-C10烷基基团,可选地具有一个或多个碳原子被羟基取代,或者R1、R2与桥接氮一起可以形成由3至10个碳原子组成的环,该环可选地还包括另一个氮、氧或硫原子,和/或环上的氮、氧或硫取代基,以及制备prasugrel的制备方法和使用方法。
  • [EN] IMPROVED PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND<br/>[FR] PROCÉDÉ AMÉLIORÉ DE FABRICATION DE COMPOSÉ PHARMACEUTIQUE
    申请人:EGIS GYOGYSZERGYAR NYILANOSAN MUKOEDO RESZVENYTARSASAG
    公开号:WO2011077173A1
    公开(公告)日:2011-06-30
    The object of the present invention is a one-pot process for preparing the 2-acetoxy-5-(2-fluoro-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]-pyridine (prasugrel) of the formula (I) by reacting the 5,6,7,7a-tetrahydro-4H-tieno[3,2-c]-pyridine-2-on of the formula (II) with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)-etanone of the formula (III) or with 2-chloro-l-cyclopropyl-2-(2-fluorphenyl)-etanone of the formula (IIIa) and acetylating of the formed compound of the formula (IV), wherein the reaction is carried out in the presence of an organic base with an acetylation agent without isolating the compound of the formula (IV). The coupling and acetylation are carried out in the presence of the same organic base such as triethylamine, N,N-diisopropyl-ethylamine or pyridine. At the end of the process the prasugrel of the formula (I) is purified by recrystallization from an organic solvent or a mixture of solvents.
    本发明的对象是通过将式(II)的5,6,7,7a-四氢-4H-噻吩[3,2-c]-吡啶-2-酮与式(III)的2-溴-1-环丙基-2-(2-氟苯基)-乙酮或与式(IIIa)的2-氯-1-环丙基-2-(2-氟苯基)-乙酮反应,并使生成的化合物(IV)乙酰化,从而制备式(I)的2-乙酰氧基-5-(2-氟-α-环丙基-羰基苯基)-4,5,6,7-四氢-4H-噻吩[3,2-c]-吡啶(prasugrel)的一锅法工艺,其中在有机碱和乙酰化剂的存在下进行反应,而无需分离式(IV)的化合物。偶联和乙酰化是在存在相同有机碱的情况下进行的,例如三乙胺、N,N-二异丙基乙胺或吡啶。在过程结束时,通过从有机溶剂或溶剂混合物中再结晶来纯化式(I)的prasugrel。
  • [EN] PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE COMPOSÉS PHARMACEUTIQUES ET COMPOSÉS INTERMÉDIAIRES
    申请人:EGIS GYOGYSZERGYAR NYILANOSAN MUKOEDO RESZVENYTARSASAG
    公开号:WO2011077174A1
    公开(公告)日:2011-06-30
    The object of the present invention is a process for preparing the 2-acetoxy-5-(2-fluor-α- cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts form crystalline 5-trityl-4,5,6,7-tetrahydro-tieno[3,2- c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7- tetrahydro-tieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof.
    本发明的对象是一种制备式(I)的2-乙酰氧基-5-(2-氟-α-环丙基甲酰基苯基)-4,5,6,7-四氢-4H-噻吩[3,2-c]吡啶(prasugrel)的方法。该方法从晶态式(VI)的5-三苄基-4,5,6,7-四氢-噻吩[3,2-c]吡啶开始。本发明的另外目的是5-三苄基-4,5,6,7-四氢-噻吩[3,2-c]吡啶的两种新型晶体形式(VI)及其用于制备式(V)化合物的使用和制备方法。
  • [EN] METHOD FOR PREPARING PHARMACEUTICALLY ACTIVE INGREDIENT AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UNE SUBSTANCE PHARMACEUTIQUEMENT ACTIVE ET DE SES INTERMÉDIAIRES
    申请人:EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDO RESZVENYTARSASAG
    公开号:WO2012052788A1
    公开(公告)日:2012-04-26
    The present invention is related to a safe and industrially applicable method for the preparation of 2-acetoxy-5-(2-fluoro-α-cyclopropyl- carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-thieno[3,2-c]pyridine in a quality suitable for use as pharmaceutically active ingredient wherein the concentration of the impurities of the Formula.(XXIV) or (XXIVa) is reduced.
    本发明涉及一种安全且适用于工业生产的方法,用于制备2-乙酰氧基-5-(2-氟-α-环丙基-羰基苄基)-4,5,6,7-四氢-4H-噻吩[3,2-c]吡啶,其质量适合用作药用活性成分,其中减少了公式(XXIV)或(XXIVa)的杂质浓度。
  • PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND
    申请人:Porcs-Makkay Márta
    公开号:US20130030183A1
    公开(公告)日:2013-01-31
    The object of the present invention is a one-pot process for preparing the 2-acetoxy-5-(2-fluoro-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]-pyridine (prasugrel) of the formula (I) by reacting the 5,6,7,7a-tetrahydro-4H-tieno[3,2-c]-pyridine-2-on of the formula (II) with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)-etanone of the formula (III) or with 2-chloro-1-cyclopropyl-2-(2-fluorphenyl)-etanone of the formula (IIIa) and acetylating of the formed compound of the formula (IV), wherein the reaction is carried out in the presence of an organic base with an acetylation agent without isolating the compound of the formula (IV). The coupling and acetylation are carried out in the presence of the same organic base such as triethylamine, N,N-diisopropyl-ethylamine or pyridine. At the end of the process the prasugrel of the formula (I) is purified by recrystallization from an organic solvent or a mixture of solvents.
    本发明的对象是一种一锅法制备2-乙酰氧基-5-(2-氟-α-环丙基-羰基-苯甲基)-4,5,6,7-四氢-4H-噻吩[3,2-c]-吡啶(prasugrel)的方法,通过将式(II)的5,6,7,7a-四氢-4H-噻吩[3,2-c]-吡啶-2-酮与式(III)的2-溴-1-环丙基-2-(2-氟苯基)-乙酮或式(IIIa)的2-氯-1-环丙基-2-(2-氟苯基)-乙酮反应,并使生成的化合物(IV)进行乙酰化,其中反应在有机碱和乙酰化剂的存在下进行,而无需分离式(IV)的化合物。偶联和乙酰化在同一有机碱的存在下进行,如三乙胺、N,N-二异丙基乙胺或吡啶。在过程结束时,通过在有机溶剂或溶剂混合物中重结晶来纯化式(I)的prasugrel。
查看更多

同类化合物

钠3-氨基-4,6-二甲基噻吩并[2,3-b]吡啶-2-羧酸酯 脱乙酰基2-O-叔-丁基二甲基硅烷基普拉格雷 羟基(噻吩并[2,3-b]吡啶-3-基)乙腈 盐酸噻氯匹定 甲基4-溴7-氧-6,7-二氢噻吩并[2,3-C]吡啶-2-羧酸酯 甲基3-甲基噻吩并[2,3-c]吡啶-2-羧酸酯 甲基3-氨基噻吩并[2,3-c]吡啶-2-羧酸酯 甲基3-氨基-4-(二甲基氨基)噻吩并[2,3-b]吡啶-2-羧酸酯 甲基3-氨基-4,5,6-三甲基噻吩并[2,3-b]吡啶-2-羧酸酯 甲基2,4-二甲基噻吩并[3,4-b]吡啶-7-羧酸酯 替诺立定 普拉格雷羟基硫内酯 普拉格雷盐酸盐 普拉格雷杂质III 普拉格雷杂质1 普拉格雷杂质 普拉格雷 外消旋-2-(2-氯苯基)-(6,7-二氢-4H-噻吩并[3,2-c]吡啶-5-基)乙腈 噻氯吡啶杂质F 噻氯吡啶杂质E 噻氯匹定杂质8 噻氯匹定N-氧化物 噻氯匹定3-氯异构体 噻氯匹定 噻氯匹丁-d4 噻吩并吡啶酮 噻吩并吡啶-2-甲酸甲酯 噻吩并[3,4-b]吡啶-5,7-二酮 噻吩并[3,2:3,4]环戊二烯并[1,2-b]吖丙因(9CI) 噻吩并[3,2-c]吡啶-3-胺 噻吩并[3,2-c]吡啶-3-羧醛 噻吩并[3,2-c]吡啶-2-羧酸甲酯 噻吩并[3,2-c]吡啶-2-羧酸 噻吩并[3,2-c]吡啶-2-基硼酸 噻吩并[3,2-c]吡啶 噻吩并[3,2-b]吡啶-7-羧酸 噻吩并[3,2-b]吡啶-6-醇 噻吩并[3,2-b]吡啶-6-胺 噻吩并[3,2-b]吡啶-6-羧酸甲酯 噻吩并[3,2-b]吡啶-6-羧酸 噻吩并[3,2-b]吡啶-5-羧酸 噻吩并[3,2-b]吡啶-3-胺 噻吩并[3,2-b]吡啶-2-羧酸甲酯 噻吩并[3,2-b]吡啶-2-羧酸 噻吩并[3,2-b]吡啶-2-甲醇 噻吩并[3,2-C]吡啶-2-硼酸频那醇酯 噻吩并[3,2-B]吡啶-3-羧酸甲酯 噻吩并[2,3-c]吡啶-7-胺 噻吩并[2,3-c]吡啶-7-羧酸甲酯 噻吩并[2,3-c]吡啶-7-羧酸